A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia. - Wikidata - wikimedia - TriplyDB

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

http://www.wikidata.org/entity/Q34378396

about

Isocitrate dehydrogenase mutations in myeloid malignancies.Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments.

P2860

Q37625630-DD7C932A-D642-4AB3-8F15-C6AEE27A709B Q38033592-CFE888BC-BC40-4858-87EA-4402337B5C92

P2860

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

http://www.wikidata.org/entity/Q34378396

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

@ast

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

@en

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

@nl

type

label

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

@ast

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

@en

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

@nl

prefLabel

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

@ast

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

@en

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

@nl

P1433

Q34378396-2B702077-EF61-4E8F-B623-8AA861FB05B2

P1476

Q34378396-5240D5BC-D2E4-4AD8-9F2B-B9FBCBF908EC

P2093

Q34378396-023275A1-39D8-433E-BA3C-D56D69432149

Q34378396-1F53A5BE-3AA2-4869-83EB-25768BD427A5

Q34378396-6529772F-CBF5-437B-898E-71DD57CD3722

Q34378396-6553DE1A-3F22-4AE2-802D-EB61AA78446C

Q34378396-8A8185FA-13E7-4895-AA6E-445B5662F7D1

Q34378396-9C1C6E59-EEFE-4ED4-A403-A84DEB569979

Q34378396-E2520293-C94A-42EF-8B47-1B30B12CB28C

Q34378396-F9E51560-34BC-4568-934E-5DED44038D00

P2860

Q34378396-18D7EEF8-9FDE-4E1C-9144-7F6BF19BEA4D

Q34378396-1DF4EA7A-34E9-4E33-B516-8ADFFAD48B77

Q34378396-20E0ABA2-B954-4798-8DE4-CF715BB14550

Q34378396-4D0228BF-8536-4F9E-BFB2-636A8411DD30

Q34378396-62E35404-C16F-47BE-B090-670158D97B4A

Q34378396-65C46748-E819-4E76-9C6C-128921FA7B2D

Q34378396-A9AA0B96-ECAB-4E5B-A544-EEAB9D72C81D

Q34378396-AC1320E7-43DF-432D-84C7-47CBEF4FED00

Q34378396-B5B122B3-45B6-46BE-904D-ABB308AD3984

Q34378396-CBC17B76-7BEE-40FF-9FCE-6925C360C7E3

P2888

Q34378396-9A922403-0F12-49EF-941A-B1E6FFC6926A

P304

Q34378396-64069CB5-E820-419C-9EA5-EC9F320A127B

P31

Q34378396-7945783D-485A-4958-B02E-D11627CBAA8D

P356

Q34378396-BDC7E578-E5E9-4046-9604-5B7A4003F417

P433

Q34378396-36E930FC-92DF-4883-9334-16B25518BF28

P478

Q34378396-9ED7CFAD-127E-46A1-AE4E-54EDA81FD095

P50

Q34378396-19B11ABF-746E-4711-80FB-4B29D34DB61F

Q34378396-3EB42F07-2C72-4361-B0C1-2C7281C48EC8

Q34378396-579D04FB-0366-429A-A242-BC8AC2053DF6

Q34378396-944C8B6B-615B-4E25-82D7-9A46E160F860

Q34378396-AF78F8D9-D5B5-4C5E-810B-C54AB09845A5

Q34378396-B0C2D9EA-A8C2-481E-9AF5-65529876BA65

P577

Q34378396-DF60AD2C-C5BF-46CF-BCAD-0B7E06BDD72C

P6179

Q34378396-46E7D5CF-94BC-48D4-BFDB-97CF9C56312F

P698

Q34378396-81E50E84-F3F7-42C8-AECF-64889D24642B

P921

Q34378396-EBE8B726-6044-4D9D-88DF-A52B3E4D752D

P932

Q34378396-72188439-0EA6-49A5-BE6D-28022A4AF631

P356

S10637-009-9369-7

P1433

Investigational New Drugs

P1476

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.

@en

P2093

Boris K Lin

http://www.w3.org/2001/XMLSchema#string

Deborah Thomas

http://www.w3.org/2001/XMLSchema#string

Isam Abdel-Karim

http://www.w3.org/2001/XMLSchema#string

Karen B Schneck

http://www.w3.org/2001/XMLSchema#string

Min Du

http://www.w3.org/2001/XMLSchema#string

Steven J Nicol

http://www.w3.org/2001/XMLSchema#string

Victor J Chen

http://www.w3.org/2001/XMLSchema#string

William K Plunkett

http://www.w3.org/2001/XMLSchema#string

P2860

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.

Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors.

Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.

Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules.

Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.

Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.

Understanding the cancer biology universe: enigmas, context and future prospects.

Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia.

Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer.

P2888

s10637-009-9369-7

P304

323-331

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-009-9369-7

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

P577

2010-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1013581227

http://www.w3.org/2001/XMLSchema#string

P698

20091088

http://www.w3.org/2001/XMLSchema#string

P921

P932

4204658

http://www.w3.org/2001/XMLSchema#string